Home - Products - JAK/STAT Signaling - STAT - Nirsevimab

Nirsevimab

CAS No. 1989556-22-0

Nirsevimab( —— )

Catalog No. M36818 CAS No. 1989556-22-0

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	1264	In Stock
10MG	2014	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Nirsevimab
Note

Research use only, not for human use.
Brief Description

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.
Description

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

JAK/STAT Signaling
Target

STAT
Recptor

RSV
Research Area

——
Indication

——

Chemical Information

CAS Number

1989556-22-0
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Griffin MP, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. ?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

XZH-5

XZH-5 is a small moelcule that inhibits constitutive and interleukin-6-induced STAT3 phosphorylation.
C188-9 (b)

A novel small-molecule STAT3 inhibitor with Ki of 12.4 nM; inhibits STAT3 binding to its pY-peptide ligand.
MMPP

MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.

Sign In Join Free